Vitamin Shoppe, Inc (NYSE:VSI) had its target price lowered by Barclays PLC from $6.00 to $3.00 in a research report sent to investors on Thursday morning. The firm currently has an equal weight rating on the specialty retailer’s stock.

Several other research firms also recently issued reports on VSI. Zacks Investment Research upgraded Vitamin Shoppe from a strong sell rating to a hold rating in a research report on Tuesday, July 18th. BidaskClub downgraded Vitamin Shoppe from a hold rating to a sell rating in a research report on Thursday, July 27th. Morgan Stanley set a $8.00 target price on Vitamin Shoppe and gave the stock a hold rating in a research report on Thursday, August 10th. Goldman Sachs Group, Inc. (The) restated a sell rating and set a $6.00 target price (down previously from $13.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Finally, Deutsche Bank AG restated a hold rating and set a $7.00 target price (down previously from $14.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. Vitamin Shoppe has an average rating of Hold and a consensus target price of $5.00.

Vitamin Shoppe (NYSE VSI) remained flat at $$3.50 during trading hours on Thursday. The company’s stock had a trading volume of 709,398 shares, compared to its average volume of 511,542. The stock has a market cap of $83.92, a PE ratio of 3.71 and a beta of 0.74. Vitamin Shoppe has a 12 month low of $2.95 and a 12 month high of $26.60. The company has a quick ratio of 0.34, a current ratio of 2.07 and a debt-to-equity ratio of 0.59.

Vitamin Shoppe (NYSE:VSI) last posted its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.20). The company had revenue of $288.20 million for the quarter, compared to analysts’ expectations of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The company’s revenue was down 8.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.50 EPS. research analysts expect that Vitamin Shoppe will post 0.72 earnings per share for the current year.

WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/vitamin-shoppe-inc-vsi-price-target-lowered-to-3-00-at-barclays-plc/1694462.html.

In other news, Director John D. Bowlin purchased 40,000 shares of the firm’s stock in a transaction dated Friday, August 25th. The shares were purchased at an average price of $5.50 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now owns 56,028 shares in the company, valued at approximately $308,154. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.07% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new position in shares of Vitamin Shoppe in the third quarter worth $243,000. GMT Capital Corp bought a new position in shares of Vitamin Shoppe in the third quarter worth $3,423,000. Systematic Financial Management LP increased its holdings in shares of Vitamin Shoppe by 94.9% in the third quarter. Systematic Financial Management LP now owns 217,345 shares of the specialty retailer’s stock worth $1,163,000 after purchasing an additional 105,855 shares during the period. Dynamic Technology Lab Private Ltd increased its holdings in shares of Vitamin Shoppe by 335.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 77,389 shares of the specialty retailer’s stock worth $414,000 after purchasing an additional 59,628 shares during the period. Finally, Macquarie Group Ltd. bought a new position in shares of Vitamin Shoppe in the third quarter worth $101,000. 98.39% of the stock is currently owned by hedge funds and other institutional investors.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Analyst Recommendations for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.